Efficacy and safety profiles of manidipine compared with amlodipine: A meta-analysis of head-to-head trials by RICHY, FLORENT F & LAURENT, STEPHANE
    Correspondence: Florent F. Richy, Public Health, Epidemiology and Health Economics, University of Liege faculty of medicine, Belgium. E-mail: fb968192@
skynet.be   
  (Received     3     June     2010    ; accepted     9     August     2010    ) 
                                                ORIGINAL ARTICLE       
  Efﬁ  cacy and safety proﬁ  les of manidipine compared with amlodipine: 
A meta-analysis of head-to-head trials           
        FLORENT F.         RICHY    1       &               STEPHANE         LAURENT    2       
    1    Department of Public Health, Epidemiology and Health Economics, University of Liege Faculty of Medicine, 
Belgium,     2    Department of Pharmacology, Pompidou European Hospital, INSERM U 970, 
and Paris Descartes University, Paris, France                                                           
  Abstract 
  The aim of this meta-analysis was to compare the efﬁ  cacy and safety proﬁ  le of manidipine 20 mg with that of amlodipine 
10 mg. A systematic research of quantitative data produced or published between 1995 and 2009 was performed. Head-
to-head randomized controlled trials (RCTs) of 12 months minimum duration reporting comparative efﬁ  cacy (changes in 
systolic and diastolic blood pressure) and safety (total adverse events and ankle oedema), were included. Four high-quality 
RCTs, accounting for 838 patients (436 received manidipine and 402 received amlodipine) were included. The efﬁ  cacy of 
manidipine and amlodipine was statistically equivalent: effect size for DBP          0.08 (  p        0.22) and SBP          0.01 (  p        
0.83). The global safety of manidipine was signiﬁ  cantly better than amlodipine: the relative risk (RR) for adverse event was 
0.69 (0.56  –  0.85), and particularly for ankle oedema RR was 0.35 (0.22  –  0.54). Publication bias was not signiﬁ  cant and the 
robustness of the analyses was good. These data suggest a better efﬁ  cacy/safety ratio of manidipine over amlodipine.   
    Key Words:     Ankle oedema    ,    calcium antagonists    ,    hypertension    ,    meta-analysis       
  Introduction 
  Hypertension is a major risk factor for myocardial 
infarction and the most important modiﬁ  able risk 
factor for stroke (1,2). Hypertension is also the most 
important risk factor for disability-adjusted life-years 
and mortality in developed countries and lower mor-
tality in developing countries (3). In addition, hyper-
tension severely impacts the quality of life among 
patients (2,4). Despite all beneﬁ  ts demonstrated in 
response to blood pressure lowering, hypertension 
management remains suboptimal among western 
populations (1,5). The reasons have been repeatedly 
analysed (2), among which the side-effects of antihy-
pertensive drugs emerge as an important issue in 
clinical practice. 
  Dihydropyridine calcium-channel blockers (CCBs) 
are potent antihypertensive agents. Their vasodila-
tory effects are associated with adverse effects 
(AEs)  such as peripheral oedema, headache and 
ﬂ   ushing (6). Ankle oedema is a common adverse 
event observed during treatment with CCBs, and 
mainly dihydropyridines, and is dose related (6,7). 
The three mechanisms put forward to explain the 
formation of ankle oedema after CCBs are the arte-
riolar vasodilation, the impairment of the local vas-
cular autoregulation of blood ﬂ  ow and the impaired 
protection against hydrostatic load (7). This adverse 
event has an early onset, since it is observed during 
the ﬁ  rst 2 weeks of treatment, is dose dependent and 
is more frequent in elderly patients (7). 
  In several cases, ankle oedema is responsible for 
treatment discontinuation or limited patient  ’  s com-
pliance to anti-hypertensive treatment and has a 
deleterious impact on health-related quality of life. 
Manidipine, a third-generation CCB characterized 
by high lipophilicity and vasoselective action, has 
demonstrated a better tolerability proﬁ  le than short-
acting calcium antagonists requiring multiple daily 
doses (e.g. nifedipine, felodipine), delayed or modiﬁ  ed-
released formulations (e.g. nifedipine) and agents 
with longer half-life (e.g. amlodipine). Indeed, in 
clinical pharmacological studies using the pretibial 
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subcutaneous tissue pressure technique (7) and foot  –
  ankle volume measurement (5), ankle oedema was 
less frequent with manidipine than with amlodipine, 
felodipine and nifedipine. 
  Ankle oedema is related to the baroreﬂ  ex-
induced activation of the sympathetic system, con-
stricting the post-capillary venules, thus reinforcing 
the pressure gradient at the capillary level, which 
originates from pre-capillary arteriolodilatation and 
post-capillary venoconstriction (7). Hydrostatic 
pressure aggravates the phenomenon of capillary 
transudation (7). Manidipine proved to induce less 
ankle oedema than other dihydropyridines, pro-
bably because of a lower degree of sympathetic acti-
vation (8  –  11). 
  The objective of the present study was to com-
pare the efﬁ  cacy and safety proﬁ  le of manidipine 
with that of amlodipine, currently the most pre-
scribed dihydropyridine. Several randomized paral-
lel groups clinical studies concluded to a similar 
or even better antihypertensive efﬁ  cacy of manid-
ipine, compared with amlodipine, with less frequent 
side-effects (8  –  11). We used a meta-analysis of ran-
domized controlled trials (RCTs), since the statisti-
cal power of each trial is rather limited and cannot 
by itself provide a clear-cut estimate of the relative 
efﬁ   cacy and safety of manidipine compared with 
amlodipine.     
  Methods 
  A systematic research of any controlled trial con-
taining relevant data was performed using validated 
methods (Cochrane), followed by peer review, data 
extraction and quality scoring blinded for authors 
and data sources. An exhaustive systematic search 
has been performed, using a maximum of sources 
(Medline, Premedline, Embase, Cochrane con-
trolled trials register, manual review of the literature 
and congresses abstracts). Inclusion criteria were: 
RCT, duration of 1 month at least, amlodipine as 
comparator, assessment of efﬁ  cacy of systolic and 
diastolic blood pressure reduction, global side-
effects and ankle oedema using validated tech-
niques, publication range January 1995 to July 
2009. Leading authors were contacted for unpub-
lished data. The publications retrieved were dis-
cussed for methodological standards and inclusion 
compatibility by two separate authors. We did our 
best to provide as robust assumptions as possible. 
To this end, analyses were performed using profes-
sional dedicated software in a conservative fashion. 
The number of patients presenting with the 
researched outcomes were preferentially used 
against the number of events (12). 
  Dichotomical outcomes were expressed as relative 
risk (RR  Riskexposed /Risknon-exposed) or risk differences 
(RD  Riskexposed – Risknon-exposed). Continuous outcomes 
were  expressed as standardized mean differences 
(i.e. effect sizes): (ES  Meanexposed – Meannon-exposed /
[(Std(Mean)]exposed, non-exposed)). 
  The level of statistical signiﬁ  cance was set at 5% 
for association and 10% for heterogeneity. The 
intergroup difference was assessed on the basis of 
heterogeneity over 10%. The global and individual 
estimators were surrounded by their 95% conﬁ  dence 
intervals. Publication bias (the bias related to the 
preferential publication of trials reporting signiﬁ  cant 
efﬁ  cacy) was exhaustively investigated using funnel 
plot representation and formal assessments involving 
Fail Safe N, regression intercept method and rank 
correlation approach (13). All operations were per-
formed using a registered copy of Comprehensive 
Meta-Analysis 2.2.040 (Biostat Inc, USA) (14).     
  Results 
  Four studies, accounting for 838 patients exposed to 
either to manidipine 10  –  20 mg or amlodipine for 
12  –  48 weeks were ultimately included in the meta-
analytic process (8  –  11) (Table I).   
  Efﬁ  cacy: ofﬁ  ce diastolic and systolic blood pressures 
  Amlodipine and manidipine reported a statistically 
similar efﬁ  cacy in the reduction of diastolic and sys-
tolic blood pressure. Effect sizes were     0.085 (    0.22 
to 0.092) and     0.015 (    0.15 to 0.12), respectively 
(Table II). On average, systolic blood pressure was 
reduced by 18.3 and 17.3 mmHg, and diastolic 
blood pressure was reduced by 8.5 and 10.5 mmHg 
after manidipine and amlodipine, respectively.     
  Safety: total AEs 
  The relative risk for developing any AEs when allo-
cated to manidipine was signiﬁ  cantly lower [RR      
0.69 (0.56  –  0.85);   p        0.001] than after amlodipine. 
In terms of risk difference, a signiﬁ  cant 11% (5  –  17%) 
reduction of the risk for adverse event was computed 
in favour of manidipine (Table III).     
  Safety: ankle oedema 
  The pooled relative risk for developing ankle oedema 
was 0.35 (0.23  –  0.54) for manidipine against amlo-
dipine. In terms of risk difference, a signiﬁ  cant 11.3% 
(7  –  16%) reduction of the risk for ankle oedema was 
computed in favour of manidipine (Table IV).     
  Publication bias 
  No evidence of signiﬁ  cant publication bias was found 
in the dataset. When adjusting the safety analysis of 
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bias, the point estimate remained signiﬁ  cantly  in 
favour of manidipine, suggesting a good robustness 
of the analyses (Table V and Figure 1).       
  Discussion 
  The present study demonstrated that, despite a sim-
ilar antihypertensive efﬁ  cacy, manidipine 10  –  20 mg 
was associated with signiﬁ   cantly less total AEs in 
general, and ankle oedema in particular, compared 
with amlodipine 5  –  10 mg in the long-term manage-
ment of mild to moderate hypertension in patients 
aged over 35 years. 
  The high rate of uncontrolled blood pressure 
remains a major issue in most countries (2). The 
causes have been analysed in several reviews (15), 
among them poor persistence with therapy (16,17), 
most often related to patient intolerance for AEs. 
Although dihydropyridine CCBs are powerful anti-
hypertensive agents, their vasodilatory effects are 
associated with AEs such as peripheral oedema, 
headache and ﬂ   ushing (6). Pharmacokinetic and 
pharmacodynamic difference between dihydropyri-
dines could lead to a lower incidence of vasodilation 
related AEs with the third-generation molecules, like 
manidipine, compared with second-generation mol-
ecules like amlodipine. Amlodipine is particularly 
interesting to compare, since this is the most pre-
scribed dihydropyridine in most countries. 
  Our working hypothesis was that ankle oedema 
would occur to a lesser extent after manidipine than 
after amlodipine, despite a similar antihypertensive 
efﬁ   cacy. Indeed, although all dihydropyridines 
CCBs have been developed to reach similar BP low-
ering efﬁ   cacy despite different potency, they may 
differ in sympathetic activation. The high lipophilic-
ity and vasoselective action of manidipine could rep-
resent an advantage regarding baroreﬂ  ex activation, 
know as a key element in the pathophysiology of 
ankle oedema. It is generally accepted that in 
response to blood pressure lowering after dihydro-
pyridines, the baroreﬂ  ex-induced activation of the 
sympathetic system leads to contraction of post-
capillary venules, which in turn increases the pressure 
gradient at the capillary level. Hydrostatic pressure 
aggravates the phenomenon of capillary transuda-
tion (7). In the meantime, pre-capillary arteriolodi-
latation, a direct effect of dihydropyridines, protects 
against the vasoconstrictive effects of sympathetic 
activation (7,18,19). 
  Recent pharmacodynamic studies have shown that 
manidipine induced a lower degree of sympathetic 
activation than amlodipine, which in turn could 
explain the lower incidence of ankle oedema. In a ran-
domized crossover trial, with a 4-week placebo run-in 
period at baseline and a 4-week placebo wash-out 
period between the 16-week treatment periods, Fogari 
et al. (19) demonstrated that, compared with amlo-
dipine, manidipine was associated with signiﬁ  cantly 
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    Table III. Meta-analysis of the adverse effects (AEs) in response to either manidipine or amlodipine during head-to-head studies, 
expressed either as risk ratio (RR, upper part) or risk difference (RD, lower part).   
Study name
AMANDHA
MARIMBA
MH: Mentel-Haenszel method.
MAISH
Zanchetti et al
Total AEs
Total AEs
Total AEs
Total AEs
24
12
12
48
MH risk
ratio
Lower
limit
Upper
limit Z-Value p-Value
Favours Manidipine Favours  Amlodipine
Favours Manidipine Favours  Amlodipine
0,526
0,754
0,227
0,167
0,691
0,511
0,592
0,087
0,021
0,562
0,435
0,023
0,003
0,088
0,001
0.1 0,2 0,5 1 2 5 10
–0,25 –0,13 0,00 0,13 0,25
1,335
0,961
0,595
1,307
0,851
–0,780
–2,281
–3,019
–1,705
–3,478
Outcome Time point MH risk ratio and 95%Cl
MH risk difference and 95%Cl
Statistics for each study
Study name
MAISH
Zanchetti et al
AMANDHA
MARIMBA
Total AEs
Total AEs
Total AEs
Total AEs
12
48
24
12
MH risk
difference
Standard
error Variance
Lower
limit
Upper
limit Z-Value p-Value
–0,049
–0,100
–0,283
–0,156
–0,110
0,063
0,043
0,095
0,076
0,031
–0,171
–0,184
–0,459
–0,304
–0,171
0,074
–0,015
–0,097
–0,008
–0,048
–0,783
–2,313
–2,984
–2,068
–3,504
0,434
1,021
0,003
0,039
0,000
0,004
0,002
0,009
0,006
0,001
Comparison Time point Statistics for each study
    Table II. Meta-analysis of the blood pressure lowering effect in response to either manidipine or amlodipine during head-to-head 
studies.   
Study name
AMANDHA
MARIMBA
MAISH
Zanchetti et al
SBP
SBP
SBP
SBP
24
12
12
48
0,628
Std diff
in means
Standard
error Variance
Lower
limit
Upper
limit Z-Value p-Value
–0,067
0,096
–0,154
–0,015
0,228
0,250
0,143
0,091
0,070
0,181
–0,557
–0,185
–0,331
–0,151
1,074
0,420
0,377
0,024
0,122
2756
–1,267
0,669
–1,696
–0,211
0,006
1,789
0,503
0,090
0,833
–1,00 –0,50
Favours Amlodipine Favours Manidipine
0,00 0,50 1,00
0,052
0,063
0,021
0,008
0,005
Comparison Time point Statistics for each study Std diff in means and 95% Cl
Study name
AMANDHA
MARIMBA
MAISH
Zanchetti et al
DBP
DBP
DBP
DBP
24
12
12
48
–0,579
Std diff
in means
Standard
error Variance
Lower
limit
Upper
limit Z-Value p-Value
–0,087
0,053
–0,061
–0,085
0,227
0,250
0,143
0,090
0,070
–1,024
–0,577
–0,227
–0,238
–0,221
–0,134
0,404
0,334
0,116
0,052
–2,756
–0,347
0,372
–0,675
–1,217
0,011
1,729
0,710
0,500
0,224
–1,00 –0,50
Favours Amlodipine Favours Manidipine
0,00 0,50 1,00
0,052
0,063
0,021
0,008
0,005
Comparison Time point Statistics for each study Std diff in means and 95% Cl
      SBP, ofﬁ  ce systolic blood pressure; DBP, ofﬁ  ce diastolic blood pressure. Mean differences (and standard errors) are displayed.     58   F. F. Richy   &   S. Laurent   
smaller increases in morning and evening ankle vol-
ume. Plasma norepinephrine levels were not sig-
niﬁ   cantly altered during the 16-week manidipine 
treatment period, but signiﬁ  cantly increased during 
the corresponding amlodipine treatment period. There 
was a signiﬁ  cant positive correlation between changes 
in norepinephrine levels and ankle volume during 
amlodipine therapy, particularly in the morning, but 
this was not the case during manidipine therapy. 
  In the present study, we demonstrated that, 
despite a similar antihypertensive efﬁ  cacy,  manid-
ipine 10  –  20 mg was associated with signiﬁ  cantly less 
ankle oedema, compared with amlodipine 5  –  10 mg, 
in the long-term management of mild to moderate 
hypertension. 
  Several limitations should be discussed, as with 
all meta-analyses. Although carrying a high level of 
evidence, modern meta-analyses may be biased by 
selective publication of positive trials. The present data-
set was tested for robustness against this assumption 
and no signiﬁ  cant difference in the overall estimates 
could be found while adjusting for potential publica-
tion bias. RCTs can be limited in their ability to 
identify rare adverse events, as they are not sufﬁ  -
ciently powered. Post-marketing authorization stud-
ies can allow regulatory bodies and pharmaceutical 
industries to detect safety signals; however, their 
ability to draw inferences against comparators is very 
limited because of the heterogeneity of patients 
included. In this perspective, meta-analysis allows 
for more precise comparison of the relative risks of 
adverse events, as they keep the randomization 
scheme of the original studies. Heterogeneity was 
present in efﬁ  cacy outcomes, although it was non-
signiﬁ  cant in safety outcomes. This can be attributed 
to the differences in inclusion criteria, leading to 
variability in response, although the relative safety of 
manidipine against amlodipine appeared to be stable. 
A random effect combination model was used to 
account for this, according to current guidelines. 
    Table IV. Meta-analysis of ankle oedema in response to either manidipine or amlodipine during head-to-head studies, expressed either 
as risk ratio (RR, upper part) or risk difference (RD, lower part).   
Study name
AMANDHA
MARIMBA
MAISH
Zanchetti et al
Ankle Oedema
Ankle Oedema
Ankle Oedema
Ankle Oedema
24
12
12
48
MH risk
ratio
Lower
limit
Upper
limit Z-Value p-Value
Favours Manidipine Favours  Amlodipine
Favours Manidipine Favours  Amlodipine
0,431
0,383
0,083
0,333
0,354
0,137
0,236
0,011
0,037
0,232
0,149
0,000
0,019
0,330
0,000
0.1 0,2 0,5 1 2 5 10
–0,25 –0,13 0,00 0,13 0,25
1,353
0,622
0,661
3,037
0,540
–1,442
–3,884
–2,352
–0,975
–4,828
Outcome Time point MHrisk ratio and 95%Cl
MH risk difference and 95%Cl
Statistics for each study
Study name
MAISH
Zanchetti et al
AMANDHA
MARIMBA
Ankle Oedema
Ankle Oedema
Ankle Oedema
Ankle Oedema
12
48
24
12
MH risk
difference
Standard
error Variance
Lower
limit
Upper
limit Z-Value p-Value
–0,053
–0,131
–0,183
–0,063
–0,113
0,036
0,032
0,075
0,060
0,022
–0,123
–0,193
–0,330
–0,180
–0,156
0,017
–0,070
–0,037
–0,055
–0,069
–1,493
–4,172
–2,448
–1,042
–5,088
0,135
0,000
0,014
0,298
0,000
0,001
0,001
0,006
0,004
0,000
Comparison Time point Statistics for each study
MH: Mentel-Haenszel method.
    Table V. Duval and Tweedie Trim and Fill sensitivity analysis.   
Studies 
trimmed
Fixed effects Random effects
Q value
Point 
estimate
Lower 
limit
Upper 
limit
Point 
estimate
Lower 
limit
Upper 
limit
Observed values     0.46829     0.65665     0.27993     0.76498     1.19516     0.33480 17.72861
Adjusted values 4     0.39147     0.57423     0.20872     0.46422     0.90358     0.02485 29.62359
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  In conclusion, these data suggest a better efﬁ  cacy/
safety ratio of manidipine over amlodipine. These 
results may have an important impact, since patients 
who persists with treatment have better chance of 
normalizing their blood pressure, thus reducing their 
risk of cardiovascular and renal events.     
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    Figure 1.         Publication bias assessment and robustness testing: 
funnel plot with a Duval and Tweedie Trim and Fill sensitivity 
analysis. This graph plots the log RR against the studies precision 
(open circles), as well as the log global estimate (black lozenge). 
The assumption of no publication bias is linked to a symmetrical 
distribution of the studies on the left and right sides of the global 
estimate (which shows an inverted funnel). In case of asymmetry, 
Duval and Tweedie set up a method that allows for simulating the 
  “  missing  ”   studies (open grey circles) that make the graph 
symmetrical. When including these dummy studies, a new global 
estimate can be recomputed (grey lozenge) for comparison with 
the actual global estimate. Table V provides the global estimates 
with and without correction. What can be seen is that whatever 
the correction applied (as a sensitivity analysis), the estimates 
remain signiﬁ  cant, showing that no signiﬁ  cant publication bias 
affects the dataset.   
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